Catalent vs Lonza: CDMO Comparison
How does Catalent compare to Lonza for AAV manufacturing?
Side-by-side comparison of Catalent and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (12 vs 2) — a deeper regulatory paper trail.
- Lonza carries a cleaner inspection mix — no OAI classifications versus 2 for Catalent.
- Catalent has 2 FDA warning letters on record; Lonza has none.
- Catalent has materially broader EMA GMP coverage (19 active certificates vs 3) — stronger EU footprint.
- Catalent has stronger MHRA / UK coverage (16 compliant certificates vs 5).
On a 13-modality CDMO landscape, both Catalent and Lonza qualify as AAV manufacturers; Lonza carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Catalent and Lonza qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Catalent vs Lonza
How does Catalent compare to Lonza for AAV manufacturing?
On CDMO Signal's composite Signal Score, Catalent is 76/100 and Lonza is 78/100; Catalent has 12 FDA inspections on record vs 2 for Lonza; European coverage is 35 active EMA+MHRA certificates for Catalent vs 8 for Lonza. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Catalent or Lonza?
Catalent has 12 FDA inspections on record (NAI 3 / VAI 7 / OAI 2) and 2 warning letters. Lonza has 2 FDA inspections on record (NAI 0 / VAI 2 / OAI 0) and 0 warning letters.
How do Catalent and Lonza compare on European GMP coverage?
Catalent holds 19 active EMA GMP certificates and 16 MHRA / UK certificates. Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Catalent or Lonza?
Catalent is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Lonza is matched to 1. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for AAV manufacturing — Catalent or Lonza?
Both Catalent and Lonza are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →